Tissue plasminogen activator for postvitrectomy fibrin formation
- PMID: 2109297
- DOI: 10.1016/s0161-6420(90)32618-0
Tissue plasminogen activator for postvitrectomy fibrin formation
Abstract
The authors injected 25 micrograms of recombinant tissue plasminogen activator (tPA) into the anterior chamber or vitreous cavity of 23 eyes of 22 patients with severe intraocular fibrin formation that developed after vitrectomy surgery for complicated cases of proliferative vitreoretinopathy (PVR) (13 eyes), diabetic traction retinal detachment (TRD) (7 eyes), or endophthalmitis (3 eyes). Tissue plasminogen activator injected an average (+/- standard deviation) of 73 +/- 63 hours after vitrectomy surgery resulted in complete fibrinolysis in 21 of 23 eyes and partial fibrinolysis in one eye. The mean time to fibrin resolution was 3.0 +/- 1.0 hours. Four eyes required repeat tPA injection for recurrent fibrin formation; repeat injection resulted in complete fibrinolysis in each case. The mean follow-up duration after tPA administration was 6 months. At the final follow-up examination, the retina was totally attached in 18 of 23 eyes and was partially attached in 2. Visual acuity improved in 12 eyes (52%); it was at least 20/400 in 8. Complications of tPA injection included hyphema (2 patients) and corneal stromal thickening (2 patients). Mild, transient, periocular pain that was easily managed with non-narcotic analgesia developed in three patients.
Similar articles
-
[Treatment of intraocular fibrin formation with tissue plasminogen activator after vitrectomy].Zhonghua Yan Ke Za Zhi. 1995 Jul;31(4):255-8. Zhonghua Yan Ke Za Zhi. 1995. PMID: 8745515 Chinese.
-
The use of tissue plasminogen activator in postvitrectomy cases.Int Ophthalmol. 1993 Apr;17(2):95-100. doi: 10.1007/BF00942782. Int Ophthalmol. 1993. PMID: 8407122
-
Treatment of postvitrectomy fibrin pupillary block with tissue plasminogen activator.Am J Ophthalmol. 1989 Aug 15;108(2):170-5. doi: 10.1016/0002-9394(89)90013-5. Am J Ophthalmol. 1989. PMID: 2502924
-
Tissue plasminogen activator in the treatment of vitreoretinal diseases.Semin Ophthalmol. 2000 Mar;15(1):44-50. doi: 10.3109/08820530009037850. Semin Ophthalmol. 2000. PMID: 10749314 Review.
-
Endophthalmitis after pars plana vitrectomy. The Postvitrectomy Endophthalmitis Study Group.Ophthalmology. 1995 May;102(5):705-12. doi: 10.1016/s0161-6420(95)30965-7. Ophthalmology. 1995. PMID: 7777268 Review.
Cited by
-
Tissue plasminogen activator therapy for the eye.Br J Ophthalmol. 2005 Nov;89(11):1390-1. doi: 10.1136/bjo.2005.074401. Br J Ophthalmol. 2005. PMID: 16234434 Free PMC article. No abstract available.
-
Retinal toxicity of intravitreal tenecteplase in the rabbit.Br J Ophthalmol. 2004 Apr;88(4):573-8. doi: 10.1136/bjo.2003.027466. Br J Ophthalmol. 2004. PMID: 15031179 Free PMC article.
-
A prospective, open-label, dose-escalating study of low molecular weight heparin during repeat vitrectomy for PVR and severe diabetic retinopathy.Graefes Arch Clin Exp Ophthalmol. 2005 Jul;243(7):701-5. doi: 10.1007/s00417-004-0912-0. Epub 2005 Mar 3. Graefes Arch Clin Exp Ophthalmol. 2005. PMID: 15744529
-
Increased retinal toxicity of intravitreal tissue plasminogen activator in a central retinal vein occlusion model.Graefes Arch Clin Exp Ophthalmol. 2008 Apr;246(4):509-14. doi: 10.1007/s00417-007-0670-x. Epub 2007 Oct 25. Graefes Arch Clin Exp Ophthalmol. 2008. PMID: 17960414
-
Factors affecting the efficacy of antibiotics in the treatment of experimental postoperative endophthalmitis.Trans Am Ophthalmol Soc. 1993;91:775-844. Trans Am Ophthalmol Soc. 1993. PMID: 8140709 Free PMC article. Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials